Biased Ligands. Better Drugs.

Press Releases

4/1/14 - Trevena CEO to Present at the 13th Annual Needham Healthcare Conference

Trevena, Inc. (NASDAQ: TRVN), today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 2:20 p.m. ET in New York City. Read More

4/1/14 - Trevena Appoints Robert Prachar as SVP, Commercial and Corporate Strategy
Trevena, Inc. (NASDAQ: TRVN), today announced the appointment of Robert Prachar to the newly created position of Senior Vice President, Commercial and Corporate Strategy, effective immediately. Mr. Prachar, who has served as a full-time consultant for the Company since August 2013, brings over 20 years of commercial leadership experience in the life sciences industry. Read More

3/20/14 - Trevena Reports Full Year 2013 Financial Results
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced financial results for the year ended December 31, 2013. Read More

3/13/14 - Trevena to Host Conference Call on March 20th to Discuss Full Year 2013 Financial Results
Trevena, Inc. (NASDAQ: TRVN), today announced that it will host a conference call on Thursday, March 20, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2013. Read More

3/7/14 - Trevena Announces Partial Exercise of Underwriters’ Overallotment Option
Trevena, Inc. (NASDAQ: TRVN), today announced that the underwriters for its initial public offering of common stock have partially exercised their over-allotment option and purchased an additional 270,449 shares. Read More

3/5/14 - Trevena CEO to Present at the Barclays Global Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 11, 2014 at 10:45 a.m. ET in Miami, FL. Read More

2/5/14 - Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain
Trevena, Inc. (NASDAQ: TRVN), today announced the initiation of its first Phase 1 trial for TRV734, a novel drug candidate in development as an orally administered treatment for moderate to severe acute and chronic pain. Read More

2/5/14 - Trevena Announces Closing of Initial Public Offering
Trevena, Inc. (NASDAQ: TRVN), today announced the closing of its initial public offering of 9,250,000 shares of common stock at an initial public offering price of $7.00 per share. Read More

1/31/14 - Trevena Increases Offering
Trevena, Inc., today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share. Trevena previously announced that the number of shares in the offering was 8,500,000. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. Read More

1/30/14 - Trevena Announces Pricing of its Initial Public Offering
Trevena, Inc., today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a price of $7.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. Read More

1/9/14 - Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Fail
Trevena, Inc., announced today initiation of dosing in BLAST-AHF, the Company’s randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure (AHF). Read More

1/8/14 - Trevena Appoints Francois Nader, MD, to its Board of Directors
Trevena, Inc., announced today that Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals, Inc. has joined its Board of Directors. Read More

News Archive

Copyright © Trevena, Inc.